ArticleNPJ precision oncology2024
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 7 citations in OpenAlex.
- Cell-Type-Resolved Proteomics Reveals Distinct Immune and Metabolic Programs Between Primary and Recurrent Ascites in HGSOC.Proteomics. Clinical applications · 2026Article
- Nuclear localization of the glutaminyl-tRNA synthetase QARS reveals its role in DNA damage response in ovarian cancer.Nature communications · 2026Article
- Proteomic Profiling Identifies CLDN3 as a Tumor-Selective Therapeutic Target in Small Cell Lung Cancer.bioRxiv : the preprint server for biology · 2026Article
- Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics.NPJ precision oncology · 2026Article
- CRISP3, a Potential Tumor Suppressor, Inhibits the Progression of High-Grade Serous Ovarian Carcinoma by Modulating the PI3K/AKT Pathway.Biomedicines · 2026Article
- ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trials.ArXiv · 2025Article
- Proteogenomic characterization of invasive breast tumors in young women.NPJ breast cancer · 2025Article
- Histopathology and proteomics are synergistic for high-grade serous ovarian cancer platinum response prediction.NPJ precision oncology · 2025Article
- Laser capture microdissection.Nature reviews. Methods primers · 2025Article
- Histopathology and proteomics are synergistic for High-Grade Serous Ovarian Cancer platinum response prediction.medRxiv : the preprint server for health sciences · 2024Article
- Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches.Frontiers in oncology · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
36 authors at 20 institutions in 4 countries.
Nicholas W Bateman *Gynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. batemann@whirc.org.ORCID http://orcid.org/0000-0002-4425-9511
Tamara AbulezGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5325-5064
Anthony R SoltisThe American Genome Center, Collaborative Health Initiative Research Program, Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Andrew McPhersonDepartment of Computational Oncology, Memorial Sloan Kettering Cancer Center, Manhattan, NY, USA.
Seongmin ChoiDepartment of Computational Oncology, Memorial Sloan Kettering Cancer Center, Manhattan, NY, USA.
Dale W GarsedPeter MacCallum Cancer Centre, Parkville, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-1223-0121
Ahwan PandeyPeter MacCallum Cancer Centre, Parkville, Melbourne, Victoria, Australia.
Chunqiao TianGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Brian L HoodGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Kelly A ConradsGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Pang-Ning TengGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-7919-3567
Julie OliverGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Glenn GistGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Dave MitchellGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Tracy J LitziGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Christopher M TarneyGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Barbara A CrothersThe Joint Pathology Center, Defense Health Agency, National Capital Region Medical Directorate, Silver Spring, MD, USA.
Paulette Mhawech-FaucegliaDepartment of Anatomic Pathology, Division of Gynecologic Pathology, University of Southern California, Los Angeles, CA, USA.
Clifton L DalgardThe American Genome Center, Collaborative Health Initiative Research Program, Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2025-8239
Matthew D WilkersonThe American Genome Center, Collaborative Health Initiative Research Program, Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Mariaelena PierobonCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA.ORCID http://orcid.org/0000-0003-2084-1029
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA.
Chunhua YanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, USA.
Daoud MeerzamanCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Rockville, MD, USA.
Clara BodelonDivision of Cancer Epidemiology and Genetics National Cancer Institute, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-6578-2678
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics National Cancer Institute, Rockville, MD, USA.
Jerry S H LeeEllison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-1515-0952
APOLLO Research Network
David G HuntsmanDepartment of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
Sohrab ShahDepartment of Computational Oncology, Memorial Sloan Kettering Cancer Center, Manhattan, NY, USA.ORCID http://orcid.org/0000-0001-6402-523X
Craig D ShriverThe John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University and Walter Reed National Military Medical Center, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-8993-5811
Neil T PhippenGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Kathleen M DarcyGynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2888-2968
David D L BowtellPeter MacCallum Cancer Centre, Parkville, Melbourne, Victoria, Australia.
Thomas P Conrads *Gynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. conrads@whirc.org.ORCID http://orcid.org/0000-0003-4742-3281
G Larry Maxwell *Gynecologic Cancer Center of Excellence, Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. george.maxwell@inova.org.
Henry M. Jackson Foundation · USUniformed Services University of the Health Sciences · USNational Cancer Institute · USInova Health System · USGeorge Mason University · USMemorial Sloan Kettering Cancer Center · USPeter MacCallum Cancer Centre · AUDuke Medical Center · USThe University of Melbourne · AUUniversity of Cambridge · GBUniversity of Southern California · USWalter Reed National Military Medical Center · USDefense Health Agency · USGynecologic Oncology Group · USMayo Clinic in Arizona · USStanford University · USThe Ohio State University · USThe University of Sydney · AUThe University of Texas MD Anderson Cancer Center · USUniversity of British Columbia · CA
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MRelating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskR01CA248288 · NCI · MAYO CLINIC ROCHESTER · PI Stacey J Winham · 2021 to 2026
$4.8MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA248288
Abstract
We performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity. We identified patients with longer progression-free survival had increased immune-related signatures and validated proteins correlating with tumor-infiltrating lymphocytes in 65 tumors from an independent cohort of HGSOC patients, as well as with overall survival in an additional 126 HGSOC patient cohort. We identified that homologous recombination deficient (HRD) tumors are enriched in pathways associated with metabolism and oxidative phosphorylation that we validated in independent patient cohorts. We further identified that polycomb complex protein BMI-1 is elevated in HR proficient (HRP) tumors, that elevated BMI-1 correlates with poor overall survival in HRP but not HRD HGSOC patients, and that HRP HGSOC cells are uniquely sensitive to BMI-1 inhibition.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.